Primary Amyloidosis Clinical Trials

Find Primary Amyloidosis Clinical Trials Near You

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Has a diagnosis of ATTR-CM

• Is initiating treatment with vutrisiran or another approved ATTR-CM therapy

Locations
United States
Florida
Clinical Trial Site
RECRUITING
Naples
New Jersey
Clinical Trial Site
RECRUITING
New Brunswick
Tennessee
Clinical Trial Site
RECRUITING
Memphis
Contact Information
Primary
Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-ALNYLAM
Backup
Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-256-9526
Time Frame
Start Date: 2026-01-09
Estimated Completion Date: 2030-10-23
Participants
Target number of participants: 2000
Treatments
Patients with ATTR-CM
Patients with ATTR-CM.
Related Therapeutic Areas
Sponsors
Leads: Alnylam Pharmaceuticals

This content was sourced from clinicaltrials.gov